Akhil Munjal1, Bhavtosh Dedania2, Brooks Cash3. 1. Department of Internal Medicine, University of Texas Health Science Center at Houston/McGovern Medical School, 6431 Fannin Street, Houston, TX, 77030, USA. 2. Division of Gastroenterology, University of Texas Health Science Center at Houston/McGovern Medical School, 6431 Fannin Street, MSB 4.234, Houston, TX, 77030, USA. 3. Division of Gastroenterology, University of Texas Health Science Center at Houston/McGovern Medical School, 6431 Fannin Street, MSB 4.234, Houston, TX, 77030, USA. brooks.d.cash@uth.tmc.edu.
Abstract
PURPOSE OF REVIEW: Irritable bowel syndrome (IBS) is a functional GI disorder that affects a large percentage of the population and presents a significant socio-economic burden on the society. In this article, we reviewed the evidence supporting various pharmacological treatment options for IBS. RECENT FINDINGS: Rifaximin, eluxadoline, and alosetron have demonstrated that they reduce symptom severity improving quality of life in patients with IBS-diarrhea. Ramosetron is a promising agent in development. Peppermint oil has also demonstrated a positive impact on some symptoms of IBS. For IBS with constipation, traditional laxatives have failed to demonstrate significant benefit. However, lubiprostone, linaclotide, and plecanatide have demonstrated improvement of IBS with constipation in large, placebo-controlled trials. Tenapanor, a sodium/hydrogen exchanger 3 inhibitor, appears to be a promising treatment option in the pipeline. There are multiple pharmacologic agents with a variety of mechanisms that have demonstrated efficacy in IBS with diarrhea and constipation. There are no established pharmacologic agents for IBS with a mixed bowel pattern. There is a promising pipeline for additional novel therapies for IBS.
PURPOSE OF REVIEW: Irritable bowel syndrome (IBS) is a functional GI disorder that affects a large percentage of the population and presents a significant socio-economic burden on the society. In this article, we reviewed the evidence supporting various pharmacological treatment options for IBS. RECENT FINDINGS:Rifaximin, eluxadoline, and alosetron have demonstrated that they reduce symptom severity improving quality of life in patients with IBS-diarrhea. Ramosetron is a promising agent in development. Peppermint oil has also demonstrated a positive impact on some symptoms of IBS. For IBS with constipation, traditional laxatives have failed to demonstrate significant benefit. However, lubiprostone, linaclotide, and plecanatide have demonstrated improvement of IBS with constipation in large, placebo-controlled trials. Tenapanor, a sodium/hydrogen exchanger 3 inhibitor, appears to be a promising treatment option in the pipeline. There are multiple pharmacologic agents with a variety of mechanisms that have demonstrated efficacy in IBS with diarrhea and constipation. There are no established pharmacologic agents for IBS with a mixed bowel pattern. There is a promising pipeline for additional novel therapies for IBS.
Authors: Jeffrey W Jacobs; Michael R Leadbetter; Noah Bell; Samantha Koo-McCoy; Christopher W Carreras; Limin He; Jill Kohler; Kenji Kozuka; Eric D Labonté; Marc Navre; Andrew G Spencer; Dominique Charmot Journal: ACS Med Chem Lett Date: 2022-04-11 Impact factor: 4.632
Authors: Erin D Lewis; Joseph M Antony; David C Crowley; Amanda Piano; Renu Bhardwaj; Thomas A Tompkins; Malkanthi Evans Journal: Nutrients Date: 2020-04-21 Impact factor: 5.717
Authors: Judy Nee; Katherine Salley; Andrew G Ludwig; Thomas Sommers; Sarah Ballou; Eve Takazawa; Sarah Duehren; Prashant Singh; Johanna Iturrino; Jesse Katon; Ha-Neul Lee; Vikram Rangan; Anthony J Lembo Journal: Clin Transl Gastroenterol Date: 2019-12 Impact factor: 4.488